KNX-101

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain. Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor. Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation. KNX-101 is under development by Kinoxis Therapeutics. As of January 2026, it is in the preclinical research stage of development.

KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain. Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor. Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation. KNX-101 is under development by Kinoxis Therapeutics. As of January 2026, it is in the preclinical research stage of development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365260891 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.